{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:27:05Z","timestamp":1791584825952,"version":"4.3.4"},"reference-count":115,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":2095,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.14283\/jpad.2018.43","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T02:10:22Z","timestamp":1614305422000},"page":"2-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":247,"title":["Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research"],"prefix":"10.1016","volume":"6","author":[{"given":"Harald","family":"Hampel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-M.","family":"Mesulam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Cuello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Khachaturian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vergallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Farlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Giacobini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.S.","family":"Khachaturian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2018.43_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jalz.2009.01.022","article-title":"Prevent Alzheimer's disease by 2020: a national strategic goal","volume":"5","author":"Khachaturian","year":"2009","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jalz.2015.10.002","article-title":"The Special Topics Section of Alzheimer's & Dementia","volume":"11","author":"Khachaturian","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib3","author":"OECD.","year":"2013","journal-title":"OECD Analytical Report on Dementia: Emerging trends in biomedicine and health technology innovation: addressing the global challenge of Alzheimer's"},{"key":"10.14283\/jpad.2018.43_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3233\/JAD-2009-0971","article-title":"Methodological issues in primary prevention trials for neurodegenerative dementia","volume":"16","author":"Andrieu","year":"2009","journal-title":"J. Alzheimers Dis"},{"key":"10.14283\/jpad.2018.43_bib5","first-page":"123","article-title":"Can we prevent Alzheimer's disease","volume":"9","author":"Carrillo","year":"2013","journal-title":"Secondary \u00abprevention\u00bb trials in Alzheimer's disease. Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jalz.2013.03.008","article-title":"New and different approaches needed for the design and execution of Alzheimer's clinical trials","volume":"9","author":"Carrillo","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jalz.2011.01.001","article-title":"Global issues in drug development for Alzheimer's disease","volume":"7","author":"Doody","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jalz.2006.04.003","article-title":"Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease","volume":"2","author":"Mohs","year":"2006","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jalz.2013.03.007","article-title":"Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU\/US\/CTAD Task Force","volume":"9","author":"Vellas","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12603-012-0044-x","article-title":"Alzheimer's disease therapeutic trials: EU\/US Task Force report on recruitment, retention, and methodology","volume":"16","author":"Vellas","year":"2012","journal-title":"J. Nutr. Health Aging"},{"key":"10.14283\/jpad.2018.43_bib11","first-page":"1","article-title":"The paradox of reearch on dementia\u2013Alzheimer's disease","volume":"4","author":"Khachaturian","year":"2015","journal-title":"J. Prev. Alzheimers Dis"},{"key":"10.14283\/jpad.2018.43_bib12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0028-3908(65)90025-0","article-title":"Amnesic properties of scopolamine and brain acetylcholine in the rat","volume":"4","author":"Pazzagli","year":"1965","journal-title":"Int. J. Neuropharmacol."},{"key":"10.14283\/jpad.2018.43_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00404606","article-title":"Differential impairment of delayed matching in monkeys by scopolamine and scopolamine methylbromide","volume":"11","author":"Bohdanecky","year":"1967","journal-title":"Psychopharmacologia"},{"key":"10.14283\/jpad.2018.43_bib14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1126\/science.174.4011.788","article-title":"The cholinergic synapse and the site of memory","volume":"174","author":"Deutsch","year":"1971","journal-title":"Science"},{"key":"10.14283\/jpad.2018.43_bib15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/brain\/90.3.497","article-title":"The ascending cholinergic reticular system: neocortical, olfactory and subcortical projections","volume":"90","author":"Shute","year":"1967","journal-title":"Brain"},{"key":"10.14283\/jpad.2018.43_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/archneur.1974.00490320001001","article-title":"Human memory and the cholinergic system. A relationship to aging","volume":"30","author":"Drachman","year":"1974","journal-title":"Arch Neurol"},{"issue":"3","key":"10.14283\/jpad.2018.43_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/brain\/99.3.459","article-title":"Neurotransmitter\u2013related enzymes and indices of hypoxia in senile dementia and other abiotrophies","volume":"99","author":"Bowen","year":"1976","journal-title":"Brain"},{"key":"10.14283\/jpad.2018.43_bib18","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer's disease","volume":"2","author":"Davies","year":"1976","journal-title":"Lancet"},{"key":"10.14283\/jpad.2018.43_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0091-3057(76)90286-0","article-title":"Short\u2013term memory in the rhesus monkey: disruption from the anti\u2013cholinergic scopolamine","volume":"5","author":"Bartus","year":"1976","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.14283\/jpad.2018.43_bib20","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1126\/science.227061","article-title":"Physostigmine and recent memory: effects in young and aged nonhuman primates","volume":"206","author":"Bartus","year":"1979","journal-title":"Science"},{"key":"10.14283\/jpad.2018.43_bib21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.14283\/jpad.2018.43_bib22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0006-8993(76)90385-1","article-title":"Acetylcholinesterase\u2013rich projections from the basal forebrain of the rhesus monkey to neocortex","volume":"109","author":"Mesulam","year":"1976","journal-title":"Brain Res"},{"key":"10.14283\/jpad.2018.43_bib23","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7058341","article-title":"Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain","volume":"215","author":"Whitehouse","year":"1982","journal-title":"Science"},{"key":"10.14283\/jpad.2018.43_bib24","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.6338589","article-title":"Alzheimer's disease: a disorder of cortical cholinergic innervation","volume":"219","author":"Coyle","year":"1983","journal-title":"Science"},{"key":"10.14283\/jpad.2018.43_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJM198507043130102","article-title":"Neurochemical studies of early\u2013onset Alzheimer's disease","volume":"313","author":"Francis","year":"1985","journal-title":"Possible influence on treatment. The New England journal of medicine"},{"key":"10.14283\/jpad.2018.43_bib26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0022-510X(81)90106-4","article-title":"Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease","volume":"51","author":"Perry","year":"1981","journal-title":"J. Neurol. Sci."},{"key":"10.14283\/jpad.2018.43_bib27","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM198611133152001","article-title":"Oral tetrahydroaminoacridine in long\u2013term treatment of senile dementia, Alzheimer type","volume":"315","author":"Summers","year":"1986","journal-title":"The New England journal of medicine"},{"key":"10.14283\/jpad.2018.43_bib28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ana.20100","article-title":"Cholinergic nucleus basalis tauopathy emerges early in the aging\u2013MCI\u2013AD continuum","volume":"55","author":"Mesulam","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.14283\/jpad.2018.43_bib29","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1586\/14737175.8.11.1703","article-title":"Cholinergic system during the progression of Alzheimer's disease: therapeutic implications","volume":"8","author":"Mufson","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"10.14283\/jpad.2018.43_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1101\/lm.69204","article-title":"The cholinergic lesion of Alzheimer's disease: pivotal factor or side show","volume":"11","author":"Mesulam","year":"2004","journal-title":"Learn. Mem."},{"key":"10.14283\/jpad.2018.43_bib31","series-title":"Alzheimer Disease","first-page":"269","article-title":"Cholinergic systems in Alzheimer's disease","author":"Geula","year":"1999"},{"key":"10.14283\/jpad.2018.43_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer's disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.14283\/jpad.2018.43_bib33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1749-6632.1985.tb37600.x","article-title":"The cholinergic hypothesis: a historical overview, current perspective, and future directions","volume":"444","author":"Bartus","year":"1985","journal-title":"Ann. N Y Acad. Sci."},{"key":"10.14283\/jpad.2018.43_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer's disease drug\u2013development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.14283\/jpad.2018.43_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late\u2013stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.14283\/jpad.2018.43_bib36","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0000000000003165","article-title":"Aphasic variant of Alzheimer disease: Clinical, anatomic, and genetic features","volume":"87","author":"Rogalski","year":"2016","journal-title":"Neurology"},{"key":"10.14283\/jpad.2018.43_bib37","first-page":"243","article-title":"Precision Medicine\u2013The golden gate for detection, treatment, and prevention of Alzheimer's disease","volume":"3","author":"Hampel","year":"2016","journal-title":"J. Prev. Alzheimers Dis"},{"key":"10.14283\/jpad.2018.43_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/13697137.2017.1287866","article-title":"A precision medicine initiative for Alzheimer's disease\u2013the road ahead to biomarker\u2013guided integrative disease modeling","author":"Hampel","year":"2017","journal-title":"Climacteric"},{"key":"10.14283\/jpad.2018.43_bib39","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrneurol.2013.223","article-title":"Alzheimer disease therapy\u2013\u2013moving from amyloid\u2013beta to tau","volume":"9","author":"Giacobini","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.14283\/jpad.2018.43_bib40","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1002\/cne.23415","article-title":"Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease","volume":"521","author":"Mesulam","year":"2013","journal-title":"J. Comp. Neurol."},{"key":"10.14283\/jpad.2018.43_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/brain\/107.1.253","article-title":"Neural inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey","volume":"107","author":"Mesulam","year":"1984","journal-title":"Brain"},{"key":"10.14283\/jpad.2018.43_bib42","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.biopsych.2012.02.025","article-title":"Cholinergic aspects of aging and Alzheimer's disease","volume":"71","author":"Mesulam","year":"2012","journal-title":"Biol. Psychiatry."},{"key":"10.14283\/jpad.2018.43_bib43","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbr.2010.11.058","article-title":"The cholinergic system in aging and neuronal degeneration","volume":"221","author":"Schliebs","year":"2011","journal-title":"Behav. Brain Res"},{"key":"10.14283\/jpad.2018.43_bib44","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cercor\/bhp232","article-title":"Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease","volume":"20","author":"Grothe","year":"2010","journal-title":"Cereb. Cortex."},{"key":"10.14283\/jpad.2018.43_bib45","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.neurobiolaging.2012.10.018","article-title":"Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease","volume":"34","author":"Grothe","year":"2013","journal-title":"Neurobiol. Aging."},{"key":"10.14283\/jpad.2018.43_bib46","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jnen\/59.4.308","article-title":"The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease","volume":"59","author":"Beach","year":"2000","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.14283\/jpad.2018.43_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-011-0831-1","article-title":"Pre\u2013and post\u2013synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease","volume":"122","author":"Potter","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.14283\/jpad.2018.43_bib48","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s004010050595","article-title":"Cholinergic fibre loss associated with diffuse plaques in the non\u2013demented elderly: the preclinical stage of Alzheimer's disease","volume":"93","author":"Beach","year":"1997","journal-title":"Acta Neuropathol"},{"key":"10.14283\/jpad.2018.43_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.nicl.2014.11.015","article-title":"Basal forebrain atrophy correlates with amyloid beta burden in Alzheimer's disease","volume":"7","author":"Kerbler","year":"2015","journal-title":"Neuroimage Clin"},{"key":"10.14283\/jpad.2018.43_bib50","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1093\/cercor\/bhv062","article-title":"Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive Impairment","volume":"26","author":"Grothe","year":"2016","journal-title":"Cereb. Cortex."},{"key":"10.14283\/jpad.2018.43_bib51","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0166-2236(81)90090-4","article-title":"Acetylcholine, aging and Alzheimer's disease","volume":"4","author":"Corkin","year":"1981","journal-title":"Trends in Neurosciences"},{"key":"10.14283\/jpad.2018.43_bib52","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1517\/14740338.2011.579899","article-title":"Drugs with anticholinergic properties: a current perspective on use and safety","volume":"10","author":"Gerretsen","year":"2011","journal-title":"Expert Opin. Drug Saf"},{"key":"10.14283\/jpad.2018.43_bib53","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.neurobiolaging.2015.07.009","article-title":"Disruption of cholinergic neurotransmission exacerbates Abeta\u2013related cognitive impairment in preclinical Alzheimer's disease","volume":"36","author":"Lim","year":"2015","journal-title":"Neurobiol. Aging."},{"key":"10.14283\/jpad.2018.43_bib54","series-title":"Nicotinic Acetylcholine Receptors in the Nervous System. 25","first-page":"367","article-title":"The cholinergic receptors system in the frontal lobe of Alzheimer patients","author":"Giacobini","year":"1988"},{"key":"10.14283\/jpad.2018.43_bib55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0079-6123(08)60916-4","article-title":"The cholinergic system in Alzheimer disease","volume":"84","author":"Giacobini","year":"1990","journal-title":"Prog. Brain Res"},{"key":"10.14283\/jpad.2018.43_bib56","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1471-4159.2011.07507.x","article-title":"Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease","author":"Fisher","year":"2012","journal-title":"J. Neurochem."},{"key":"10.14283\/jpad.2018.43_bib57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000440864","article-title":"AF710B, a Novel M1\/sigma1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease","volume":"16","author":"Fisher","year":"2016","journal-title":"Neurodegener. Dis."},{"key":"10.14283\/jpad.2018.43_bib58","first-page":"P1019","article-title":"Pro\u2013cognitive and anti\u2013inflammatory effects of AF710B, a mixed M1 muscarinic\/sigma\u20131 receptor agonist, in the McGill\u2013R\u2013Thy1\u2013APP rat model of human AD\u2013like amyloid pathology","author":"Hall","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib59","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0304-3940(86)90629-4","article-title":"Reduced number of [3H]nicotine and [3H] acetylcholine binding sites in the frontal cortex of Alzheimer brains","volume":"72","author":"Nordberg","year":"1986","journal-title":"Neurosci. Lett."},{"key":"10.14283\/jpad.2018.43_bib60","series-title":"2nd Int Symp on Senile Dementias Montrouge","first-page":"329","article-title":"Nicotinic receptors in human CNS: a biopsy study","author":"DeSarno","year":"1988"},{"key":"10.14283\/jpad.2018.43_bib61","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00213-006-0447-7","article-title":"PET imaging of cortical 11C\u2013nicotine binding correlates with the cognitive function of attention in Alzheimer's disease","volume":"188","author":"Kadir","year":"2006","journal-title":"Psychopharmacology (Berl)."},{"key":"10.14283\/jpad.2018.43_bib62","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.bcp.2011.06.039","article-title":"Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease","volume":"82","author":"Parri","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.14283\/jpad.2018.43_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/14737175.2015.995639","article-title":"Safety and clinical effects of EVP\u20136124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication","volume":"15","author":"Deardorff","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"10.14283\/jpad.2018.43_bib64","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/brain\/awh589","article-title":"Measurement of basal forebrain atrophy in Alzheimer's disease using MRI","volume":"128","author":"Teipel","year":"2005","journal-title":"Brain"},{"key":"10.14283\/jpad.2018.43_bib65","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/hbm.21111","article-title":"The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study","volume":"32","author":"Teipel","year":"2011","journal-title":"Hum. Brain Mapp"},{"key":"10.14283\/jpad.2018.43_bib66","doi-asserted-by":"crossref","first-page":"13249","DOI":"10.1038\/ncomms13249","article-title":"Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology","volume":"7","author":"Schmitz","year":"2016","journal-title":"Nat. Commun."},{"key":"10.14283\/jpad.2018.43_bib67","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.biopsych.2011.06.019","article-title":"Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer's disease","volume":"71","author":"Grothe","year":"2012","journal-title":"Biol. Psychiatry."},{"key":"10.14283\/jpad.2018.43_bib68","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jalz.2008.04.005","article-title":"Basal forebrain atrophy is a presymptomatic marker for Alzheimer's disease","volume":"4","author":"Hall","year":"2008","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib69","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3233\/JAD-132345","article-title":"Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study","volume":"40","author":"Kilimann","year":"2014","journal-title":"J. Alzheimers Dis"},{"key":"10.14283\/jpad.2018.43_bib70","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1016\/j.jalz.2013.09.011","article-title":"Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects","volume":"10","author":"Grothe","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib71","doi-asserted-by":"crossref","first-page":"e1631","DOI":"10.4088\/JCP.15m10413","article-title":"Reduced Regional Cortical Thickness Rate of Change in Donepezil\u2013Treated Subjects With Suspected Prodromal Alzheimer's Disease","author":"Cavedo","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.14283\/jpad.2018.43_bib72","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jalz.2014.10.003","article-title":"Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease","volume":"11","author":"Dubois","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib73","doi-asserted-by":"crossref","first-page":"11706","DOI":"10.1038\/s41598-017-09780-3","article-title":"Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease","volume":"7","author":"Cavedo","year":"2017","journal-title":"Scientific Reports"},{"key":"10.14283\/jpad.2018.43_bib74","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMoa010178","article-title":"Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease","volume":"345","author":"in t'Veld","year":"2001","journal-title":"The New England journal of medicine"},{"key":"10.14283\/jpad.2018.43_bib75","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.59.6.880","article-title":"Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study","volume":"59","author":"Zandi","year":"2002","journal-title":"Neurology"},{"key":"10.14283\/jpad.2018.43_bib76","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0079-6123(08)62117-2","article-title":"Effects of trophic factors on the CNS cholinergic phenotype","volume":"109","author":"Cuello","year":"1996","journal-title":"Prog. Brain Res"},{"key":"10.14283\/jpad.2018.43_bib77","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/neu.480251109","article-title":"Neurotrophic factor therapy for nervous system degenerative diseases","volume":"25","author":"Hefti","year":"1994","journal-title":"J. Neurobiol."},{"key":"10.14283\/jpad.2018.43_bib78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF02257624","article-title":"Nerve growth factor affects 11C\u2013nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report)","volume":"4","author":"Olson","year":"1992","journal-title":"J. Neural. Transm. Park. Dis. Dement. Sect."},{"key":"10.14283\/jpad.2018.43_bib79","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0166-4328(93)90141-C","article-title":"Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy","volume":"57","author":"Seiger","year":"1993","journal-title":"Behav. Brain Res"},{"key":"10.14283\/jpad.2018.43_bib80","series-title":"The Pharmacology of Neurotrophic Factors. In: Cuello C, Collier B, editors. Pharmacologic Sciences: Perspectives for Research and Therapy in the Late 1990s","author":"Cuello","year":"1995"},{"key":"10.14283\/jpad.2018.43_bib81","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000017069","article-title":"Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease","volume":"9","author":"Eriksdotter Jonhagen","year":"1998","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.14283\/jpad.2018.43_bib82","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13195-016-0195-9","article-title":"Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second\u2013generation encapsulated cell biodelivery device","volume":"8","author":"Eyjolfsdottir","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"10.14283\/jpad.2018.43_bib83","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm1239","article-title":"A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease","volume":"11","author":"Tuszynski","year":"2005","journal-title":"Nat. Med."},{"key":"10.14283\/jpad.2018.43_bib84","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2015.1807","article-title":"Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease","volume":"72","author":"Tuszynski","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.14283\/jpad.2018.43_bib85","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1073\/pnas.0510645103","article-title":"Activity\u2013dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade","volume":"103","author":"Bruno","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.14283\/jpad.2018.43_bib86","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/NEN.0b013e3181aed9e6","article-title":"Amyloid beta\u2013induced nerve growth factor dysmetabolism in Alzheimer disease","volume":"68","author":"Bruno","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.14283\/jpad.2018.43_bib87","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/brain\/awt372","article-title":"Nerve growth factor metabolic dysfunction in Down's syndrome brains","volume":"137","author":"Iulita","year":"2014","journal-title":"Brain"},{"key":"10.14283\/jpad.2018.43_bib88","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ana.410180306","article-title":"Abnormalities of the nucleus basalis in Down's syndrome","volume":"18","author":"Casanova","year":"1985","journal-title":"Ann. Neurol."},{"key":"10.14283\/jpad.2018.43_bib89","doi-asserted-by":"crossref","first-page":"170276","DOI":"10.1155\/2012\/170276","article-title":"Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease","volume":"2012","author":"Wilcock","year":"2012","journal-title":"Curr. Gerontol. Geriatr. Res."},{"key":"10.14283\/jpad.2018.43_bib90","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jalz.2016.05.001","article-title":"An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation","volume":"12","author":"Iulita","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib91","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1523\/JNEUROSCI.1144-11.2012","article-title":"Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype","volume":"32","author":"Allard","year":"2012","journal-title":"J. Neurosci."},{"key":"10.14283\/jpad.2018.43_bib92","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild\u2013to\u2013moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"The New England journal of medicine"},{"key":"10.14283\/jpad.2018.43_bib93","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild\u2013to\u2013moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"The New England journal of medicine"},{"key":"10.14283\/jpad.2018.43_bib94","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hup.942","article-title":"The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine","volume":"23","author":"Fredrickson","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"10.14283\/jpad.2018.43_bib95","doi-asserted-by":"crossref","first-page":"21688","DOI":"10.1371\/journal.pone.0021688","article-title":"Detecting subtle changes in visuospatial executive function and learning in the amnestic variant of mild cognitive impairment","volume":"6","author":"Papp","year":"2011","journal-title":"PLoS One"},{"key":"10.14283\/jpad.2018.43_bib96","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.neuropsychologia.2008.04.010","article-title":"Specific impairments in visuospatial working and short\u2013term memory following low\u2013dose scopolamine challenge in healthy older adults","volume":"46","author":"Thomas","year":"2008","journal-title":"Neuropsychologia"},{"key":"10.14283\/jpad.2018.43_bib97","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jalz.2014.01.009","article-title":"Microdosing of scopolamine as a \u00abcognitive stress test\u00bb: rationale and test of a very low dose in an at\u2013risk cohort of older adults","volume":"10","author":"Snyder","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib98","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long\u2013term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double\u2013blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"key":"10.14283\/jpad.2018.43_bib99","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000051272","article-title":"Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease","volume":"12","author":"Doody","year":"2001","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.14283\/jpad.2018.43_bib100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2318-5-3","article-title":"Rivastigmine: an open\u2013label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years","volume":"5","author":"Farlow","year":"2005","journal-title":"BMC Geriatr"},{"key":"10.14283\/jpad.2018.43_bib101","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0924-977X(00)00067-5","article-title":"Long\u2013term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open\u2013label study","volume":"10","author":"Rogers","year":"2000","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.14283\/jpad.2018.43_bib102","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0278-5846(01)00326-8","article-title":"Long\u2013term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits","volume":"26","author":"Doraiswamy","year":"2002","journal-title":"Prog. Neuropsychopharmacol Biol. Psychiatry."},{"key":"10.14283\/jpad.2018.43_bib103","first-page":"260","article-title":"An enriched\u2013population, doubleblind, placebo\u2013controlled, crossover study of tacrine and lecithin in Alzheimer's disease","volume":"7","author":"Foster","year":"1996","journal-title":"The Tacrine 970\u20136 Study Group. Dementia."},{"key":"10.14283\/jpad.2018.43_bib104","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.281.15.1401","article-title":"Cholinergic markers in elderly patients with early signs of Alzheimer disease","volume":"281","author":"Davis","year":"1999","journal-title":"JAMA."},{"key":"10.14283\/jpad.2018.43_bib105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0531-5565(00)00206-0","article-title":"Donepezil\u2013induced REM sleep augmentation enhances memory performance in elderly, healthy persons","volume":"36","author":"Schredl","year":"2001","journal-title":"Exp. Gerontol."},{"key":"10.14283\/jpad.2018.43_bib106","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000090630","article-title":"Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy","volume":"21","author":"Davis","year":"2006","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.14283\/jpad.2018.43_bib107","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s007020200089","article-title":"Inhibition of acetyl\u2013and butyrylcholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit","volume":"109","author":"Giacobini","year":"2002","journal-title":"J. Neural. Transm. (Vienna)."},{"key":"10.14283\/jpad.2018.43_bib108","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1468-1331.2003.00757.x","article-title":"Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients","volume":"11","author":"Almkvist","year":"2004","journal-title":"Eur. J. Neurol."},{"key":"10.14283\/jpad.2018.43_bib109","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jalz.2012.01.002","article-title":"Effectiveness of antidementia drugs in delaying Alzheimer's disease progression","volume":"9","author":"Rountree","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2018.43_bib110","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cell.2013.07.003","article-title":"SnapShot: pathobiology of Alzheimer's disease","volume":"154","author":"Selkoe","year":"2013","journal-title":"Cell"},{"key":"10.14283\/jpad.2018.43_bib111","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.2174\/138161206778792985","article-title":"Targeting beta\u2013amyloid pathogenesis through acetylcholinesterase inhibitors","volume":"12","author":"Castro","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.14283\/jpad.2018.43_bib112","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer's disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.14283\/jpad.2018.43_bib113","author":"Gauthier","year":"2018","journal-title":"Optimal use of cholinergic drugs in Alzheimer's disease"},{"key":"10.14283\/jpad.2018.43_bib114","author":"Hampel","year":"2018","journal-title":"Dawn of Alzheimer Precision Pharmacology and the Renaissance of Cholinergic drugs"},{"key":"10.14283\/jpad.2018.43_bib115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","article-title":"Practice guideline update summary: Mild cognitive impairment Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Petersen","year":"2018","journal-title":"Neurology"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724004941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724004941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T19:52:04Z","timestamp":1736452324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724004941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2274580724004941"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2018.43","relation":{"is-cited-by":[{"id-type":"doi","id":"10.3389\/fnagi.2019.00290","asserted-by":"object"},{"id-type":"doi","id":"10.3389\/fncel.2020.577912","asserted-by":"object"},{"id-type":"doi","id":"10.3389\/fnins.2019.00038","asserted-by":"object"}]},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2018.43","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}